GT201600142A - Composiciones farmacéuticas que comprenden azd9291 - Google Patents
Composiciones farmacéuticas que comprenden azd9291Info
- Publication number
- GT201600142A GT201600142A GT201600142A GT201600142A GT201600142A GT 201600142 A GT201600142 A GT 201600142A GT 201600142 A GT201600142 A GT 201600142A GT 201600142 A GT201600142 A GT 201600142A GT 201600142 A GT201600142 A GT 201600142A
- Authority
- GT
- Guatemala
- Prior art keywords
- pharmaceutical compositions
- compositions including
- methyl
- compositions
- azd9291
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1400034.3A GB201400034D0 (en) | 2014-01-02 | 2014-01-02 | Pharmaceutical Compositions comprising AZD9291 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201600142A true GT201600142A (es) | 2019-08-12 |
Family
ID=50191689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201600142A GT201600142A (es) | 2014-01-02 | 2016-06-29 | Composiciones farmacéuticas que comprenden azd9291 |
Country Status (37)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| US10513509B2 (en) | 2016-05-26 | 2019-12-24 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
| CN108057036B (zh) * | 2016-11-07 | 2023-06-13 | 正大天晴药业集团股份有限公司 | 一种egfr抑制剂的固体药物组合物 |
| CN107176954B (zh) * | 2017-06-02 | 2019-01-11 | 无锡双良生物科技有限公司 | 一种egfr抑制剂的药用盐及其晶型、制备方法和应用 |
| CN110013468B (zh) * | 2018-01-09 | 2022-02-18 | 北京福元医药股份有限公司 | 一种azd9291氘代衍生物药物制剂 |
| WO2019138346A1 (en) * | 2018-01-10 | 2019-07-18 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of osimertinib |
| MA51823A (fr) * | 2018-02-12 | 2021-05-19 | Astrazeneca Ab | Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules |
| HRP20250115T1 (hr) * | 2018-03-01 | 2025-05-23 | Astrazeneca Ab | Farmaceutski pripravci koji sadrže (2s)-{(1s)-1-cijano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil} -1,4-oksazepan-2-karboksamid |
| EP3769764B1 (en) * | 2018-03-23 | 2024-10-30 | Wuxi Shuangliang Biotechnology Co., Ltd. | Pharmaceutical composition and preparation method therefor and uses thereof |
| CA3106269A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| CN113645976A (zh) | 2019-03-29 | 2021-11-12 | 阿斯利康(瑞典)有限公司 | 用于治疗非小细胞肺癌的奧希替尼 |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| WO2021148396A1 (en) | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| TW202304457A (zh) * | 2021-03-22 | 2023-02-01 | 瑞典商阿斯特捷利康公司 | 配製物 |
| AU2023246862A1 (en) | 2022-03-31 | 2024-10-31 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
| WO2023209086A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds for treating cancer |
| WO2023209084A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| IL317733A (en) | 2022-06-27 | 2025-02-01 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for cancer treatment |
| CN119654152A (zh) | 2022-07-08 | 2025-03-18 | 阿斯利康(瑞典)有限公司 | 与hgf-受体抑制剂组合用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂 |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| WO2025092926A1 (zh) * | 2023-10-31 | 2025-05-08 | 浙江同源康医药股份有限公司 | 一种嘧啶类衍生物的药物组合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110376A (en) * | 1993-08-02 | 1998-08-16 | Bristol Myers Squibb Co | Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof |
| SE9802973D0 (sv) * | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| WO2001076565A1 (fr) * | 2000-04-12 | 2001-10-18 | Banyu Pharmaceutical Co., Ltd. | Compositions et preparations se desintegrant dans la cavite buccale |
| US6881737B2 (en) | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
| RU2318518C2 (ru) | 2002-02-26 | 2008-03-10 | Астразенека Аб | Фармацевтическая композиция, обладающая антипролиферативным действием (варианты), способ ее получения и способы с ее использованием |
| US20080102133A1 (en) * | 2004-10-05 | 2008-05-01 | Antje Brueck-Scheffler | Oral Pharmaceutical Preparation for Proton Pump Antagonists |
| ES2279715B1 (es) * | 2005-12-26 | 2008-06-01 | Laboratorios Lesvi, S.L. | Formulacion oral de olanzapina. |
| BRPI0707671A2 (pt) * | 2006-02-09 | 2011-05-10 | Daiichi Sankyo Co Ltd | composiÇço farmacÊutica anti-cÂncer |
| JP5576922B2 (ja) * | 2006-04-20 | 2014-08-20 | 信越化学工業株式会社 | 腸溶性固体分散体を含んでなる固形製剤 |
| AU2008274941A1 (en) * | 2007-07-12 | 2009-01-15 | Tragara Pharmaceuticals, Inc. | Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders |
| EP2696857A1 (en) | 2011-04-11 | 2014-02-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical composition comprising bosentan |
| KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| EP3333161B1 (en) * | 2011-07-27 | 2020-02-19 | Astrazeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer |
| CA2860973C (en) * | 2012-01-13 | 2021-10-26 | Xspray Microparticles Ab | A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component. |
| WO2013160916A1 (en) | 2012-04-25 | 2013-10-31 | Hetero Research Foundation | Sunitinib malate solid dispersion |
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
-
2014
- 2014-01-02 GB GBGB1400034.3A patent/GB201400034D0/en not_active Ceased
- 2014-12-29 UY UY0001035933A patent/UY35933A/es not_active Application Discontinuation
- 2014-12-29 AR ARP140104947A patent/AR098989A1/es not_active Application Discontinuation
- 2014-12-31 TW TW103146652A patent/TWI702953B/zh active
-
2015
- 2015-01-02 CN CN202210324141.3A patent/CN114712362A/zh active Pending
- 2015-01-02 PE PE2016000943A patent/PE20161170A1/es unknown
- 2015-01-02 WO PCT/GB2015/050001 patent/WO2015101791A1/en not_active Ceased
- 2015-01-02 PH PH1/2016/501310A patent/PH12016501310B1/en unknown
- 2015-01-02 SM SM20210330T patent/SMT202100330T1/it unknown
- 2015-01-02 DK DK15700082.9T patent/DK3089741T3/da active
- 2015-01-02 CN CN201580003266.4A patent/CN105848647B/zh active Active
- 2015-01-02 LT LTEP15700082.9T patent/LT3089741T/lt unknown
- 2015-01-02 MY MYPI2016702433A patent/MY183536A/en unknown
- 2015-01-02 EP EP15700082.9A patent/EP3089741B1/en active Active
- 2015-01-02 CR CR20160310A patent/CR20160310A/es unknown
- 2015-01-02 JP JP2016544368A patent/JP6588915B2/ja active Active
- 2015-01-02 RS RS20210698A patent/RS61927B1/sr unknown
- 2015-01-02 PT PT157000829T patent/PT3089741T/pt unknown
- 2015-01-02 CA CA2933403A patent/CA2933403C/en active Active
- 2015-01-02 ES ES15700082T patent/ES2873226T3/es active Active
- 2015-01-02 US US15/109,170 patent/US10183020B2/en active Active
- 2015-01-02 HU HUE15700082A patent/HUE054344T2/hu unknown
- 2015-01-02 HR HRP20210749TT patent/HRP20210749T1/hr unknown
- 2015-01-02 AU AU2015204218A patent/AU2015204218B2/en active Active
- 2015-01-02 SG SG11201605339QA patent/SG11201605339QA/en unknown
- 2015-01-02 SI SI201531610T patent/SI3089741T1/sl unknown
- 2015-01-02 NZ NZ721298A patent/NZ721298A/en unknown
- 2015-01-02 PL PL15700082T patent/PL3089741T3/pl unknown
- 2015-01-02 MX MX2016008744A patent/MX367358B/es active IP Right Grant
- 2015-01-02 EA EA201691242A patent/EA034243B9/ru not_active IP Right Cessation
- 2015-01-02 KR KR1020167020731A patent/KR102336378B1/ko active Active
-
2016
- 2016-06-13 IL IL246186A patent/IL246186B/en active IP Right Grant
- 2016-06-22 CL CL2016001609A patent/CL2016001609A1/es unknown
- 2016-06-22 DO DO2016000156A patent/DOP2016000156A/es unknown
- 2016-06-29 GT GT201600142A patent/GT201600142A/es unknown
- 2016-07-01 NI NI201600098A patent/NI201600098A/es unknown
- 2016-08-01 ZA ZA2016/05300A patent/ZA201605300B/en unknown
-
2018
- 2018-11-20 US US16/196,185 patent/US20190111057A1/en not_active Abandoned
-
2020
- 2020-08-04 US US16/984,276 patent/US20200360378A1/en not_active Abandoned
-
2021
- 2021-06-08 CY CY20211100499T patent/CY1124848T1/el unknown
- 2021-09-17 US US17/478,117 patent/US20240189310A1/en not_active Abandoned
-
2022
- 2022-04-26 US US17/729,162 patent/US20220395502A1/en not_active Abandoned
-
2024
- 2024-09-26 US US18/897,609 patent/US20250017930A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201600142A (es) | Composiciones farmacéuticas que comprenden azd9291 | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| CO7310528A2 (es) | Composición farmacéutica recubierta que contiene regorafenib | |
| BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
| AR090073A1 (es) | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos | |
| EA201591150A1 (ru) | Твердая единая форма с высоким содержанием фексофенадина и способ ее получения | |
| EA202090913A1 (ru) | Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон | |
| UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| CO2018014217A2 (es) | Composiciones farmacéuticas que comprenden safinamida | |
| CO2017004382A2 (es) | Composiciones farmacéuticas que comprenden lobeglitazona para administración oral | |
| WO2014125504A3 (en) | Pharmaceutical compositions of febuxostat | |
| MD20180049A2 (ro) | Compoziţie farmaceutică | |
| EA201890477A1 (ru) | Инкапсулированная композиция финголимода | |
| BR112017012965A2 (pt) | derivados de fumagilol | |
| AR100175A1 (es) | Inhibidores de autotaxina | |
| BR112016026422A2 (pt) | solução farmacêutica compreendendo dopamina para uso no tratamento da doença de parkinson | |
| EA201991288A1 (ru) | Фармацевтические композиции на основе дабигатрана | |
| AR134057A2 (es) | Composición farmacéutica en solución acuosa | |
| CO2018005367A2 (es) | Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico | |
| CR20190401A (es) | Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas | |
| CU20130165A7 (es) | Liberación modificada de 4-metil-3-[[-4-(3- piridinil)-2-pirimidinil]amino]-n-5-(4- metil-1h-imidazol-1- il)-3- (trifluorometil) fenil] benzamida solubilizada utilizando acidos orgánicos | |
| MX366763B (es) | Composiciones farmacéuticas de montelukast y levocetirizina. | |
| BR112016029417A2 (pt) | desmopressina estabilizada | |
| IN2014MU01179A (enExample) | ||
| DOP2015000049A (es) | Composición farmacéutica recubierta que contiene regorafenib |